Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D R Camidge
Economic Evaluation of Fulvestrant as an Extra Step in the Treatment Sequence for ER-positive Advanced Breast Cancer
British Journal of Cancer
Cancer Research
Oncology
Related publications
Moesin Is an Independent Prognostic Marker for ER‑positive Breast Cancer
Oncology Letters
Cancer Research
Oncology
Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Geburtshilfe und Frauenheilkunde
Gynecology
Midwifery
Maternity
Obstetrics
Evaluating an ER Degrader for Breast Cancer
Cancer Discovery
Oncology
Genetically Engineered ER -Positive Breast Cancer Mouse Models
Endocrine-Related Cancer
Cancer Research
Endocrinology
Oncology
Metabolism
Diabetes
A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis
OncoTargets and Therapy
Oncology
Pharmacology
Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
Breast Care
Surgery
Oncology
